Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coca-Cola/FUZE

This article was originally published in The Tan Sheet

Executive Summary

Castanea Partners has completed the sale of FUZE Beverage to the Coca-Cola company, the private equity firm announces March 21. Coca-Cola said in February it would purchase the brand, including products such as Slenderize, which contains chromium for energy and SuperCitrimax to suppress appetite (1"The Tan Sheet" Feb. 26, 2007, In Brief)...

You may also be interested in...



Food claim warning letter

Labeling for several FUZE Healthy Infuzions beverages stating vitamin B3 is "known to ... reduce cholesterol levels in blood" and polyphenols are "associated with reduced risk of developing cardiovascular disease and certain cancers" violates the Food, Drug & Cosmetic Act, FDA says in a recent 1warning letter to FUZE Beverages. These claims "promote [the] products for use as drugs." Additionally, the products "are labeled with a dietary supplement disclaimer statement," the agency adds. "Because these products are conventional foods, not dietary supplements, their labels should not include this disclaimer." The dietary supplement industry voiced its concerns to FDA at a recent meeting and asked that dietary supplements and functional foods be given a level "regulatory playing field" (2"The Tan Sheet" Dec. 11, 2006, p. 3). Coca-Cola announced Feb. 1 it intends to purchase FUZE to expand its beverage portfolio...

Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971

It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.

Crosswalk: ISO 14971:2007 Vs. ISO 14971:2019

Here’s a crosswalk for recently revised international risk management standard ISO 14971 and its 2007 predecessor.

Topics

UsernamePublicRestriction

Register

PS100352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel